Quarterly report pursuant to Section 13 or 15(d)

LICENSED TECHNOLOGY - Additional Information (Details)

v3.19.2
LICENSED TECHNOLOGY - Additional Information (Details)
1 Months Ended 3 Months Ended 6 Months Ended
May 15, 2019
USD ($)
shares
Aug. 03, 2016
USD ($)
shares
Nov. 04, 2018
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
Paid due licensor current       $ 10,000,000   $ 10,000,000   $ 10,000,000
Finite-Lived Intangible Assets, Gross       42,606,000   42,606,000   44,859,000
Payable due licensor non current       20,000,000   20,000,000   $ 20,000,000
Amortization of intangible assets       $ 1,293,000 $ 87,000 2,638,000 $ 174,000  
Shares returned in connection with arbitration ruling on licensing agreement (in shares) | shares 450,000              
Non-cash loss on arbitration ruling on licensing agreement $ 367,000         $ 367,000 $ 0  
Abeona Therapeutics LLC                
Finite-lived intangible asset, useful life           20 years    
EB Agreement                
Number of license agreements research and development arrangements   2            
Issuance of common shares | shares   375,000            
Finite-Lived Intangible Assets, Gross   $ 2,450,000            
EB Agreement | Abeona Therapeutics LLC                
Finite-lived intangible asset, useful life   20 years            
REGENXBIO                
Finite-lived intangible asset, useful life     8 years          
REGENXBIO | Licensing Agreements                
Guaranteed upfront payment     $ 20,000,000          
Paid due licensor current     10,000,000          
Annual fees     100,000,000          
Milestone payment     60,000,000          
Payable due licensor non current     20,000,000          
Payment on Execution of Contracts     $ 10,000,000